Administered orally in a single dose ranging from 0.03 to 1 mg/kg, CYP4A11/CYP4F2-IN-2 proportionally decreases the production of 20-HETE in the kidneys of rats^[1].

When given intravenously at 0.5 mg/kg to mice, CYP4A11/CYP4F2-IN-2 shows a low clearance rate (1430 mL/h/kg), a moderate volume of distribution at steady state (763 mL/kg), and a short half-life (0.424 hours)^[1].

At a dosage of 1 mg/kg administered intravenously to Sprague-Dawley (SD) rats, the inhibitor demonstrates a low clearance rate (226 mL/h/kg), a moderate volume of distribution at steady state (839 mL/kg), and a half-life of approximately 3.01 hours^[1].

Following oral administration at 1 mg/kg to SD rats, CYP4A11/CYP4F2-IN-2 reaches a maximum concentration (Cmax) of 623 ng/mL, has a half-life of 3.03 hours, and exhibits high bioavailability (97.7%)^[1].

CYP4A11/CYP4F2-IN-2 effectively reduces the production of 20-Hydroxyeicosatetraenoic acid (20-HETE) from arachidonic acid within human kidney microsomes, showing an IC50 value of 29 nM^[1].